Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 03:51:06 2024-05-23 am EDT			5-day change	1st Jan Change
8.94 ^SEK	-0.67%		-0.89%	-3.25%

May. 10	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Initiator Pharma Q1 2024 - Focus on sealing a deal

May 10, 2024 at 06:30 am EDT

Redeye provides a research update following the Q1 report published by Initiator Pharma earlier today. The report did not include any significant surprises as the company continues to operate at a very low cash burn, showing promise for the financial runway ahead. Instead, we continue to argue that the full priority for 2024 will be to find a licensing partner for primarily pudafensine. We reiterate our fair value range with a base case valuation of SEK24 as we continue to have a strong outlook on the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Initiator Pharma Issues New Shares for Debt Conversion	Feb. 21	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	Jan. 08	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	23-10-06	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	23-09-19	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	23-08-09	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	23-08-09	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	23-07-18	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	23-07-05	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	23-06-29	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	23-06-05	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	23-05-25	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	23-05-02	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	23-03-06	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	22-12-20	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	22-11-04	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	22-11-04	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	22-10-02	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	22-09-21	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	-3.25%	44.38M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.13%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research

Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Initiator Pharma Q1 2024 - Focus on sealing a deal

Latest news about Initiator Pharma A/S

Chart Initiator Pharma A/S

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research